Lorundrostat PDUFA date

The PDUFA goal date for Lorundrostat in hypertension in combination with other antihypertensive drugs is 22 Dec 2026, as disclosed by Mineralys Therapeutics Inc. (MLYS).

PDUFA date
22 Dec 2026
Condition
hypertension in combination with other antihypertensive drugs

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionNCT06785454MLYSPhase 2Completed2025-12-17Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-12-22DayLorundrostatMineralys Therapeutics Inc. · MLYSCompany-disclosed PDUFA goal dateAnnounced review targethypertension in combination with other antihypertensive drugsOpen original source
Read source excerpt

We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2026-12-22DayLorundrostatMineralys Therapeutics Inc. · MLYSCompany-disclosed PDUFA goal dateAnnounced review targettreatment of hypertension in combination with other antihypertensive drugsOpen original source
Read source excerpt

The U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026